Biochemist Joanne Lemieux worked with three other U of A researchers on a new study showing that a drug that cures deadly peritonitis in cats also works well enough against the coronavirus that causes COVID-19 to fast-track it into human clinical trials. (Photo: Supplied)
Fast-tracked research leads to phase 1 clinical trials.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
The drug is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV.
First studied by U of A chemist John Vederas and biochemist Michael James following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats.
The work to test the drug against the coronavirus that causes COVID-19 was a co-operative effort between four U of A laboratories, run by Lemieux, Vederas, biochemistry professor Howard Young and the founding director of the Li Ka Shing Institute of Virology, Lorne Tyrrell. Some of the experiments were carried out by the Stanford Synchrotron Radiation Lightsource Structural Molecular Biology program.
Their findings were published today in the peer-reviewed journal Nature Communications after first being posted on BioRxIV, a research website.
“There’s a rule with COVID research that all results need to be made public immediately,” Lemieux said, which is why they were posted before being peer-reviewed.
She said interest in the work is high, with the paper being accessed thousands of times as soon as it was posted.
Lemieux explained that Vederas synthesized the compounds, and Tyrrell tested them against the SARS-CoV-2 virus in test tubes and in human cell lines. The Young and Lemieux groups then revealed the crystal structure of the drug as it binds with the protein.
”We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she said. “This will allow us to develop even more effective drugs.”
Lemieux said she will continue to test modifications of the inhibitor to make it an even better fit inside the virus.
But she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
SARS-CoV-2 antiviral
- UCLouvain discovery could counter SARS-CoV-2 virus independently of the mutations
Despite the effectiveness of vaccination campaigns worldwide, the threat posed by Covid-19 still exists. First of all, a new SARS-CoV-2 variant could very well emerge that may not respond to current ...
- Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
The pandemic caused by SARS-CoV-2 (SCoV-2) has impacted the world in many ways and the virus continues to evolve and produce novel variants with the ability to cause frequent global outbreaks.
- SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters
Myxovirus resistance (Mx) proteins have antiviral activity against multiple RNA viruses, including influenza viruses. Because SARS coronavirus 2 (SARS-CoV-2) induces strong, diffuse expression of Mx ...
- Peter J. Halfmann, PhD, on SARS-CoV-2 Interference of Influenza Virus Replication
This interference could be correlated with SARS-CoV-2-induced expression of host factors such as the antiviral gene Mx protein 1 (Mx1), they added. Halfmann and colleagues also found that the ...
- St. John's wort extract shows potent antiviral activity against SARS-CoV-2 and its variants
In the current study, the scientists have investigated the antiviral efficacy of the extract of an herbal plant, Hypericum perforatum against SARS-CoV-2 infection. The antiviral efficacy of this ...
Go deeper with Google Headlines on:
SARS-CoV-2 antiviral
Go deeper with Bing News on:
COVID-19 cure
- Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 ...
- Self-Medication, Herbs Used For Covid-19 Treatment Harmful: Doctors
A number of residents of western Badghis province use home remedies and herbs to treat coronavirus, while doctors say self- ...
- Haiti - Diaspora Covid-19 : Daily Bulletin #781
Active cases trending down - Haiti : 1.08% of the population vaccinated with 2 doses - USA : Upward trend - Dominican Republic : Positivity rate 0.99% - Quebec : Drop in hospitalizations - France : ...
- Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus. About Therma Bright Inc. Therma Bright, developer ...
- High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out
"They don't cure COVID-19 completely, but they do decrease the severity of it, so they have a really important role to play in keeping people safe," he said. The addition of oral antiviral treatments ...